Critical Contrast: BIOLASE (BLTI) vs. LeMaitre Vascular (LMAT)
BIOLASE (NASDAQ: BLTI) and LeMaitre Vascular (NASDAQ:LMAT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitabiliy, dividends, institutional ownership and risk.
Earnings and Valuation
This table compares BIOLASE and LeMaitre Vascular’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|LeMaitre Vascular||$96.40 million||6.39||$23.12 million||$0.69||47.46|
LeMaitre Vascular has higher revenue and earnings than BIOLASE.
This is a summary of current ratings for BIOLASE and LeMaitre Vascular, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
LeMaitre Vascular has a consensus price target of $28.60, indicating a potential downside of 12.67%. Given LeMaitre Vascular’s higher probable upside, analysts plainly believe LeMaitre Vascular is more favorable than BIOLASE.
This table compares BIOLASE and LeMaitre Vascular’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
LeMaitre Vascular pays an annual dividend of $0.22 per share and has a dividend yield of 0.7%. BIOLASE does not pay a dividend. LeMaitre Vascular pays out 31.9% of its earnings in the form of a dividend.
Institutional and Insider Ownership
67.1% of LeMaitre Vascular shares are owned by institutional investors. 23.7% of LeMaitre Vascular shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
LeMaitre Vascular beats BIOLASE on 9 of the 10 factors compared between the two stocks.
BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.
About LeMaitre Vascular
LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company’s product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch.
Receive News & Stock Ratings for BIOLASE Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE Inc and related stocks with our FREE daily email newsletter.